⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9454337 | 0.75 | — | — | |
| SCHEMBL4631289 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL2959144 | 0.65 | — | — | |
| SCHEMBL3939820 | 0.63 | — | — | |
| SCHEMBL6242829 | 0.63 | — | — | |
| SCHEMBL569237 | 0.63 | — | — | |
| SCHEMBL5259943 | 0.63 | — | — | |
| SCHEMBL1447877 | 0.60 | — | — | |
| SCHEMBL5026947 | 0.59 | — | — | |
| SCHEMBL23529 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045145-A1 | WRN HELICASE-INHIBITING BIS-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 广州科恩泰生物医药科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-113912617-A | Substituted tricycles and methods of use | 艾伯维公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-108349930-B | Substituted tricycles and methods of use | 艾伯维公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20190135827-A1 | Substituted Tricyclics and Method of Use | ABBVIE SARL (LU) | 2019-05-09 | — | — | US | disclosed |
| EP-3322697-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | Abbvie S.a.r.l. (LU) | 2018-05-23 | — | — | EP | disclosed |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | ABBVIE S.Á.R.L. (LU) | 2018-02-08 | — | — | US | disclosed |
| US-9840513-B2 | Substituted tricyclics and method of use | ABBVIE S.Á.R.L. (LU) | 2017-12-12 | — | — | US | disclosed |
| US-20170015675-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-01-19 | — | — | US | disclosed |
| WO-2017009804-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-01-19 | — | — | WO | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2569302-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen, Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |